FindTrial
Sign In

The Effect of Ciprofol on Hemodynamics and Postoperative Recovery Quality in Elderly Patients Undergoing Transurethral Resection of Bladder Tumor

The Effect of Ciprofol on Hemodynamics and Postoperative Recovery Quality in Elderly Patients Undergoing Transurethral Resection of Bladder Tumor

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120196
Enrollment
Unknown
Registered
2026-03-10
Start date
2025-11-27
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Ciprofol:Anesthesia Induction:Ciprofol: 0.5 mg/kg iv. , Rocuronium Bromide: 0.6 mg/kg iv. , Sufentanil: 0.3 µg/kg iv. Anesthesia Maintenance: Ciprofol: 0.8–2.4 mg/kg/h continuous infusion, Remifent
Propofol:Anesthesia Induction:Propofol: 2 mg/kg iv. , Rocuronium Bromide: 0.6 mg/kg iv. , Sufentanil: 0.3 µg/kg iv. Anesthesia Maintenance: Propofol: 4.0–12.0 mg/kg/h continuous infusion, Remifenta

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 83 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective transurethral resection of bladder tumor (TURBT); 2. Aged >=65 years with body mass index (BMI) 18-30 kg/m²; 3. American Society of Anesthesiologists (ASA) Physical Status Class I-III; 4. Free from severe dysfunction of major organs (cardiac, pulmonary, hepatic, or renal) ; 5. Provided informed consent with documented written authorization.

Exclusion criteria

Exclusion criteria: 1. ASA class IV-V; 2. Left ventricular ejection fraction (EF) <30%; Implantation of temporary/permanent cardiac pacemaker; Presence of structural heart disease; 3. Uncontrolled chronic diseases (e.g., hypertension, diabetes mellitus) ; 4. Chronic use of psychoactive medications (opioid analgesics, benzodiazepines, anxiolytics/antidepressants/antipsychotics) or alcohol dependence; 5. Hypersensitivity or contraindication to Ciprofol/Propofol or other study drugs/excipients; 6. Documented allergy to other anesthetics; 7. Anticipated difficult airway/difficult intubation during induction.

Design outcomes

Primary

MeasureTime frame
Mean Arterial Pressure;—

Secondary

MeasureTime frame
Systolic blood pressure;Heart rate;Saturation of pulse oximetry;The time during induction to achieve an NI value of 64 (Narcotrend Index).;Extubation time;PACU stay time;Incidence of perioperative adverse events;QoR-15 score on postoperative day 1 ;—

Countries

China

Contacts

Public ContactWen Lili

Sun Yat-sen University Cancer Center

wenll@sysucc.org.cn+86 139 2957 5604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026